Publications (49) Diego Martínez Urbistondo publications

2024

  1. Alcohol Drinking Impacts on Adiposity and Steatotic Liver Disease: Concurrent Effects on Metabolic Pathways and Cardiovascular Risks

    Current Obesity Reports, Vol. 13, Núm. 3, pp. 461-474

  2. Bridging Metabolic-Associated Steatotic Liver Disease and Cardiovascular Risk: A Potential Role for Ketogenesis

    Biomedicines, Vol. 12, Núm. 3

2023

  1. Comparative effects of glucagon-like peptide-1 receptors agonists, 4-dipeptidyl peptidase inhibitors, and metformin on metabolic syndrome

    Biomedicine and Pharmacotherapy, Vol. 161

  2. Corrigendum: Role of NAFLD on the health related QoL response to lifestyle in patients with metabolic syndrome: The PREDIMED plus cohort(Front. Endocrinol., (2022), 13, (868795), 10.3389/fendo.2022.868795)

    Frontiers in Endocrinology

  3. Dietary Iron, Anemia Markers, Cognition, and Quality of Life in Older Community-Dwelling Subjects at High Cardiovascular Risk

    Nutrients, Vol. 15, Núm. 20

  4. Epidemiology of Herpes Zoster in the pre-vaccination era: establishing the baseline for vaccination programme's impact in Spain

    Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin, Vol. 28, Núm. 8

  5. Estimation of fatty liver disease clinical role on glucose metabolic remodelling phenotypes and T2DM onset

    European Journal of Clinical Investigation, Vol. 53, Núm. 10

  6. Influence of epidemiological and clinical factors in the reactogenicity to Comirnaty® vaccine in health care workers of a Spanish university teaching hospital (COVIVAC study)

    Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia, Vol. 36, Núm. 4, pp. 400-407

  7. Randomized phase II clinical trial of ruxolitinib plus simvastatin in COVID19 clinical outcome and cytokine evolution

    Frontiers in Immunology, Vol. 14

  8. Repercussions of absolute and time-rated BMI “yo-yo” fluctuations on cardiovascular stress-related morbidities within the vascular-metabolic CUN cohort

    Frontiers in Endocrinology, Vol. 13

2022

  1. Diagnostic scores and scales for appraising Nonalcoholic fatty liver disease and omics perspectives for precision medicine

    Current Opinion in Clinical Nutrition and Metabolic Care, Vol. 25, Núm. 5, pp. 285-291

  2. Enoxaparin versus dalteparin or tinzaparin in patients with cancer and venous thromboembolism: The RIETECAT study

    Research and Practice in Thrombosis and Haemostasis, Vol. 6, Núm. 4

  3. Heart Rate and Mortality in Patients With Acute Symptomatic Pulmonary Embolism

    Chest, Vol. 161, Núm. 2, pp. 524-534

  4. Hematological-and Immunological-Related Biomarkers to Characterize Patients with COVID-19 from Other Viral Respiratory Diseases

    Journal of Clinical Medicine, Vol. 11, Núm. 13

  5. Interactive Role of Surrogate Liver Fibrosis Assessment and Insulin Resistance on the Incidence of Major Cardiovascular Events

    Journal of Clinical Medicine, Vol. 11, Núm. 17

  6. Liver status and outcomes in patients without previous known liver disease receiving anticoagulant therapy for venous thromboembolism

    Internal and Emergency Medicine, Vol. 17, Núm. 3, pp. 725-734

  7. Longitudinal association of dietary acid load with kidney function decline in an older adult population with metabolic syndrome

    Frontiers in Nutrition, Vol. 9

  8. Longwise Cluster Analysis for the Prediction of COVID-19 Severity within 72 h of Admission: COVID-DATA-SAVE-LIFES Cohort

    Journal of Clinical Medicine, Vol. 11, Núm. 12

  9. Machine learning insights concerning inflammatory and liver-related risk comorbidities in non-communicable and viral diseases

    World Journal of Gastroenterology, Vol. 28, Núm. 44, pp. 6230-6248

  10. Morbid liver manifestations are intrinsically bound to metabolic syndrome and nutrient intake based on a machine-learning cluster analysis

    Frontiers in Endocrinology, Vol. 13